Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma

Kim, Young Ae; Byun, Ja Min; Park, Keeho; Bae, Gi Hwan; Lee, Duk-Hyoung; Kim, Dong‐Sook; Yoon, Sung Soo; Koh, Youngil

doi:10.1182/bloodadvances.2017010819

Cited by 28 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were two,18,19 three,19,21,22 three,18,19,21 three,18,21,22 and two18,21 included studies that reported complications of neutropenia, anemia, thrombocytopenia, leukopenia, and vomiting, respectively. However, the results showed no significant heterogeneity for these five indicators, respectively (I 2 <50% and P >0.05); therefore, the fixed-effect model was applied.…”

Section: Resultsmentioning

confidence: 99%

“…According to the Egger’s test, we found no publication bias in aspects of all outcomes ( P >0.05; Table 2). Additionally, we also assessed the influence of each individual study on the combined effect size by sensitivity analysis, and the result of thrombocytopenia was inversed after removing Kim’s article19 (RR =1.11, 95% CI: 0.71–1.73, P =0.654). We did not perform sensitivity analysis for neutropenia and vomiting, since there were only two eligible studies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

<p>Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis</p>

Deng¹,

Lin²,

Shen³

et al. 2019

OTT

View full text Add to dashboard Cite

Objective To compare cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and CHOP plus etoposide (CHOPE) with regard to outcomes including efficacy and safety for patients with peripheral T-cell lymphoma (PTCL). Methods Relevant literature was searched using PubMed, Embase, Wanfang, and CNKI for eligible trials comparing CHOP with CHOPE for treatment of PTCL. The following outcomes of PTCL patients were considered: complete response (CR), partial response (PR), overall response rate (ORR), and adverse events (AEs; grade >3). Risk ratios (RRs) were appropriately derived from fixed-effects or random-effects models. Results A total of five prospective or retrospective articles with 1,560 patients were elected for the meta-analysis. There were no significant differences in CR (RR =1.11, 95% CI: 0.73–1.67, P =0.632), PR (RR =1.40, 95% CI: 0.52–3.76, P =0.504), and ORR (RR =1.25, 95% CI: 0.93–1.69, P =0.146) between the CHOP and CHOPE groups. However, AEs including anemia (RR =1.69, 95% CI: 1.33–2.16, P <0.001) and thrombocytopenia (RR =1.43, 95% CI: 1.15–1.77, P =0.001) were significantly increased in CHOPE group compared to that in CHOP group. Conclusion Meta-analysis suggested that there were no differences in therapeutic effect for patients with PTCL between CHOP and CHOPE groups with regards to CR, PR, and ORR, whereas the CHOPE group had significantly increased AEs (anemia and thrombocytopenia) compared to CHOP group.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

<p>Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis</p>

Deng¹,

Lin²,

Shen³

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…Since literature data and bio-informatic analysis suggest the functional involvement of ENPP2 in Epstein-Barr viral infection [26], and we found it to be up-regulated both in vitro and in vivo , we hypothesized that there was a link between HBV replication and the ENPP2 protein. Accordingly, one control siRNA and two ENPP2-specific siRNA sequences were used to transfect the HepG2.2.15 virus-producing cell line.…”

Section: Resultsmentioning

confidence: 99%

Proteomics Based Identification of Autotaxin As An Anti-Hepatitis B Virus Factor and a Promoter of Hepatoma Cell Invasion and Migration

She¹,

Yang²,

Hu³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Hepatitis B virus (HBV) infection is a major cause of cirrhosis and hepatocellular carcinoma. Therefore, we aimed to obtain further information on HBV pathogenesis, and to search for novel putative molecules for anti-HBV therapy. Methods: We utilized Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) to identify the secretory proteins that are differentially expressed in the HBV DNA-transfected HepG2.2.15 cell line and its parental HepG2 cell line. Immunohistochemistry (IHC) was employed to assess the clinical relevance of the observations. Small interfering (si)RNA-based silencing transfection methods were carried out to study the function of ENPP2. Results: Totally, 133 unique proteins were identified as differentially expressed in HepG2.2.15 cell line compared with HepG2 cell line. Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 precursor (ENPP2) is one of the most significantly up-regulated secretory proteins associated with HBV replication. This differential expression of ENPP2 was further validated by real-time quantitative RT-PCR, Western Blot and immunohistochemical analysis. To study the function of ENPP2, we knockdown ENPP2 expression in HepG2.2.15 cell line by RNA interference. ENPP2 silencing increased HBV replication approximately 2.3-fold by enhancing, via the type I IFN signaling pathway, HBV cccDNA (covalently closed circular DNA) translation into viral RNA. Moreover, attenuation of ENPP2 expression inhibited both the invasion and migration ability of hepatoma cells in vitro via interacting with the molecules in the tumor microenvironment. Conclusion: Our study demonstrates that ENPP2 may be a novel anti-HBV target and indicate that suppression of its expression may inhibit the invasion and migration ability of hepatoma cells.

show abstract

“…However, as it was demonstrated by a German group [5], benefit of etoposide was limited in only younger patients with normal LDH, so it would be less likely applicable to our patient population. In addition, recent evidence showed that adding etoposide to CHOP had little benefit for PTCL in Asian populations [21].…”

Section: Discussionmentioning

confidence: 99%

Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group

Wudhikarn

Bunworasate

Julamanee

et al. 2020

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Introduction: Peripheral T cell NHL (PTCL) and natural killer/T cell NHL (NKTCL) are relatively rare disorders. Data on clinical presentation, treatment and outcome are limited especially in older age groups. Methods: We identified 127 patients with PTCL and NKTCL, excluding cutaneous T/NK cell lymphoma, aged over 60 years old from Thailand nationwide multicenter registry. Results: Of 127 patients, median age of diagnosis was 67 years old. Patients aged older than 75 years old had similar characteristics to younger (60-74 years old) but higher comorbidity index. Seventy-nine patients (62.2%) received intensive/definite multi-agent chemotherapy, however, the proportion was significant lower in older patients (70.4% vs 34.5%, p b .001). After a median follow up duration of 17.3 months, 2-year progression free survival and overall survival were 38.1% and 48.5%. Univariate and multivariable analysis demonstrated older age, poor performance status and absence of definite multi-agent chemotherapy were associated with inferior survival. Definite multi-agent lymphoma specific chemotherapy was an independent factor for overall survival after adjustment for age, comorbidity index, performance status and prognostic index for T cell lymphoma. Conclusion: Despite overall poor prognosis of PTCL and NKTCL in older adults, chemotherapy could result in objective response and long-term survival in selected patients of this vulnerable age group thus emphasizing the importance of comprehensive geriatric evaluation.

show abstract

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma

Abstract: Key Points Etoposide addition/chemo-intensification has little role in first-line treatment of PTCL in Asian populations, regardless of subtype or age. Upfront hematopoietic stem-cell transplantation as consolidation seems like a legitimate choice in patients with PTCL.

Cited by 28 publications

References 23 publications

<p>Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis</p>

<p>Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis</p>

Proteomics Based Identification of Autotaxin As An Anti-Hepatitis B Virus Factor and a Promoter of Hepatoma Cell Invasion and Migration

Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group

Contact Info

Product

Resources

About